Arna Pharma and Slate Run Pharmaceuticals have finalized a significant joint venture (JV), establishing a new specialized pharmaceutical entity poised…
Read More
Tirzepatide Shows Promising Adjunct Benefits in Type 1 Diabetes Management, Meta-Analysis Presented at European Congress on Obesity Suggests
The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
CGTxchange Launches to Revitalize Shelved Cell and Gene Therapy Programs
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have officially unveiled CGTxchange, an innovative,…
Read More
New Study Reveals Oral Semaglutide Outperforms Orforglipron in Weight Loss and Tolerability
Findings presented at the 33rd European Congress on Obesity in Istanbul, Turkey, on May 15th, have provided a crucial comparative…
Read More
Biopharma Leaders Urge Dr. Richard Pazdur to Lead FDA Amidst Crisis of Confidence
The leadership void at the U.S. Food and Drug Administration (FDA) has prompted a significant groundswell of support from the…
Read More
AstraZeneca’s Targeted Treatment Offers New Hope for Stomach Cancer Patients in the UK
AstraZeneca’s groundbreaking targeted therapy, Imfinzi (durvalumab), has secured a pivotal recommendation from the National Institute for Health and Care Excellence…
Read More
Wes Streeting Resigns as UK Health Secretary Citing Loss of Faith in Labour Leadership Following Local Election Debacle
The political landscape of the United Kingdom has been significantly reshaped by the dramatic resignation of Wes Streeting, the UK…
Read More
Foundayo Demonstrates Efficacy in Sustaining Weight Loss Post-Injectable Incretin Therapy, Presenting a Novel Oral Option
On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More
FDA Approves Four Groundbreaking Cancer Drugs in May, Offering New Hope for Hematological and Solid Tumors
The U.S. Food and Drug Administration (FDA) has authorized four significant new cancer drugs in May 2026, marking a pivotal…
Read More
Isomorphic Labs Secures $2.1 Billion in Series B Funding to Accelerate AI-Driven Drug Discovery and Development
AI drug design and development firm Isomorphic Labs has successfully closed a significant $2.1 billion Series B funding round, marking…
Read More
